Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 8, Issue 5, 2013, Pages 619-623

  Rudin, Charles M ^a   Brahmer, Julie R ^a   Juergens, Rosalyn A ^a   Hann, Christine L ^a   Ettinger, David S ^a   Sebree, Rosa ^a   Smith, Ruth ^a   Aftab, Blake T ^a   Huang, Peng ^a   Liu, Jun O ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Antiangiogenic; Itraconazole; Lung cancer

Indexed keywords

ITRACONAZOLE; PEMETREXED;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DYSPNEA; FEMALE; HUMAN; LEUKOPENIA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; METASTATIC NONSQUAMOUS NON SMALL CELL LUNG CANCER; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VERTIGO;

EID: 84876411054     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31828c3950     Document Type: Article

References (19)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006;66:11520-11539.
4. Andersen S, Donnem T, Al-Saad S, et al. Angiogenic markers show high prognostic impact on survival in marginally operable non-small cell lung cancer patients treated with adjuvant radiotherapy. J Thorac Oncol 2009;4:463-471.
5. Mineo TC, Ambrogi V, Baldi A, et al. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol 2004;57:591-597.
6. Seto T, Higashiyama M, Funai H, et al. Prognostic value of expression of vascular endothelial growth factor and its ft-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 2006;53:91-96.
7. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
8. Goulart B, Ramsey S. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health 2011;14:836-845.
9. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as frst-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-1234.
10. Chong CR, Xu J, Lu J, et al. Inhibition of angiogenesis by the antifungal drug itraconazole. ACS chemical biology 2007;2:263-270.
11. Aftab BT, Dobromilskaya I, Liu JO, et al. Itraconazole inhibits angio-genesis and tumor growth in non-small cell lung cancer. Cancer Res 2011;71:6764-6772.
12. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007;25:5471-5489.
13. Hanna N, Shepherd FA, Fossella F V, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
14. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143-151.
15. A'Hern R P. Sample size tables for exact single-stage phase II designs. Stat Med 2001;20:859-866.
16. Common Terminology Criteria for Adverse Events. Version 3.0. Available at: http://ctep.cancer.gov. Accessed December 1, 2012.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
18. Jayson GC, Hicklin DJ, Ellis LM. Antiangiogenic therapy-evolving view based on clinical trial results. Nat Rev Clin Oncol 2012;9:297-303.
19. Kolata G. Hope in the lab: a special report; a cautious awe greets drugs that eradicate tumors in mice. The New York TImes 1998;May 03.